Health and Healthcare
Day Trader Alert: Biogen Idec & Another PML Case (BIIB, ELN)
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) just came out with an SEC filing showing that on December 11, 2008, regulatory agencies were notified of a confirmed case of progressive multifocal leukoencephalopathy. In other words, it found another PML case in a multiple sclerosis patient treated with TYSABRI. This is also affecting shares of its partner Elan Corp. plc (NYSE: ELN).
This was in the commercial setting in the European Union as part ofTYGRIS: TYSABRI Global Observational Program in Safety — ROW.Additional notes issued are as follows:
Shares are now trading down 8% pre-market at $43.05, but this is onvery thin trading volume and the spread appears to be very wide. As a reminder, these PML risks have been associated with TYSABRI and the company sees this from time to time now. To see how much this stock bounced off of lows after the dust settles, the 52-week trading range $37.21 to $73.59.
Elan Corp. plc (NYSE: ELN) is its partner, and its shares are down 6% pre-market at $6.74.
Jon C. Ogg
December 15, 2008
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.